(215) 792-6676

Akari Therapeutics – Securities Investigation

Akari Therapeutics – Securities Investigation

//
Posted By
/
Comment0
/
Categories

Akari Therapeutics – Class Action Filed

A class action lawsuit has been filed against Akari Therapeutics Plc (“Akari”) (NASDAQ: AKTX) and certain of its officers, on behalf of shareholders who purchased Akari securities between March 30, 2017 and May 11, 2017, both dates inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Akari’s Alleged False and/or Misleading Phase 2 PNH Trial of Coversin Statements

The class action lawsuit alleges that throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose that: its Chief Executive Officer, Dr. Gur Roshwalb, and possibly other executives, were involved in publishing false information about Akari, including the Phase 2 PNH trial of Coversin; that Akari lacked sufficient checks and protections to prevent such behavior; and that as a result of the above, Akari’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Akari’s CEO Placed On Administrative Leave

On May 11, 2017, Akari announced that Dr. Roshwalb was placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and subsequently withdrawn on April 26, 2017 by Edison Investment Research Ltd. When this information reached the public, Akari’s stock price lowered materially, which harmed investors according to the Complaint.

What If I Have Akari Therapeutics Investment Losses?

If you purchased or otherwise acquired shares in Akari Therapeutics and would like to speak privately with a securities attorney to learn more information about this investigation, please complete the form to the right or contact John Kehoe, Esq., (215) 792-6676, Ext. 801, [email protected]; Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected]; or send an e-mail to [email protected].

The Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors and consumers from corporate fraud, negligence, and other wrongdoing. Driven by a strong and principled sense of social responsibility and obtaining justice for the aggrieved, Kehoe Law Firm, P.C. represents plaintiffs seeking to recover investment losses resulting from securities fraud, breaches of fiduciary duty, corporate wrongdoing or malfeasance, those harmed by anticompetitive practices, and consumers victimized by fraud, false claims, deception or data breaches.  Together, the partners of the Kehoe Law Firm, P.C. have spent more than 30 years prosecuting precedent-setting securities and financial fraud cases in federal and state courts on behalf of institutional and individual clients.